First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
A new batch of CRLs includes fresh revelations about patritumab deruxtecan.
Ocular toxicities could be the reason.
The group cans ZW171 after “on-target, off-tumour toxicity”.
Boehringer’s Hernexeos beats Bayer’s sevabertinib to the US.
As pivotal data approach, the French group pays $210m for ex-US rights.
Duality takes its Adam9-targeting conjugate into the clinic.